Company news

Arvinas, Inc. (NASDAQ:ARVN) news

Arvinas, Inc. news releases on 6ix. Latest, Oct 1, 2026: Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2…

Arvinas, Inc. (NASDAQ:ARVN) news

Press releases & updates

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas Employees Give Back During Company-wide Impact Day

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas : Initial Statement of Beneficial Ownership (Form 3)

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Cascade Prodrug Inc. Appoints Industry Veterans Manuel (Manny) Litchman and Andres Gutierrez to Board of Directors

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting